Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)

NCT07717580 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Primary Cutaneous Anaplastic Large Cell Lymphoma

Interventions

DRUG: Brentuximab Vedotin (Bv)
DRUG: Lisaftoclax (APG-2575)

Sponsor

Peking University First Hospital

Collaborators

[object Object]